inpatient care and drug costs represented about 50% and 27% respectively of overall expenses. The increase by 24.4% polytherapy patients mean costs as compared to monotherapy raised to 72% [IC 95: 44-106%] after adjustment on age, gender and presence of severe comorbidity. CONCLUSIONS: Polytherapy in epilepsy is associated with substantial higher direct costs. OBJECTIVES:To develop a tool to estimate the first-year per member and total health plan costs associated with monitoring of MS therapies in the United States. METHODS: Data were incorporated into an interactive tool designed to allow a health plan to estimate their costs for monitoring. MS prevalence was based on the literature. The default value for the proportion of MS patients treated with immunomodulators was assumed at 95% and adjusted IMS data were used for default market share inputs. Current Procedural Terminology (CPT) codes corresponding to the monitoring and administration procedures recommended by each product's prescribing information (PI) were identified. Charges associated with each CPT code were assigned using physician fee schedule software based on Medicare charges with default values set at 150%. PI recommendations were used for the proportion being monitored and the frequency of monitoring. In cases where a PI recommended only individuals with specific characteristics undergo monitoring, a database analysis identifying all individuals with a diagnosis of MS in the i3 InVision Data Mart (Ingenix, Eden Prairie, MN) was used to estimate the proportion of patients who may require that specific monitoring. RESULTS: The tool yielded average per patient and health plan costs expected with MS therapy monitoring. The tool conservatively estimates that the average per member first-year monitoring and administration costs ranged from $0 for glatiramer acetate to $3279 for natalizumab. Based on default values, the estimated annual costs of monitoring for all MS therapies for a million member health plan is $519,451. CONCLUSIONS: Estimating the economic impact of FDA-recommended MS therapy monitoring allows health plans to more closely assess the total cost of MS. This tool allows health plans to individualize inputs to estimate the plan-specific economic impact of MS therapy monitoring.
BACKGROUND: Multiple sclerosis (MS) is a chronic, progressive disease, often accompanied by functional impairment due to walking/mobility problems (WMPs). The impact of WMPs on the use of direct healthcare resources therefore warrants further study. OBJECTIVES: Investigate the relationship between presence and severity of WMPs and hospitalisation, physician consultations, time with allied healthcare professionals and mobility aids. METHODS: Data were obtained from a cross-sectional study of 340 neurologists in France, Germany, Italy, Spain and the UK. Neurologists completed records on the next 10-12 consulting MS patients. Of the total 3572 patients, 2111 completed a questionnaire indicating their level of WMPs: none (nϭ1342), mild (nϭ271), moderate (nϭ314), or severe (nϭ184). ANOVA with Bonferroni-corrected t-tests were used to assess the relationship between WMPs and physician-reported data on hospital episodes, physician consultations, and healthcare professional time. Patient support, including use of mobility aids, was analyzed using Chi-square with Bonferroni-adjusted Fisher's-Exact tests. RESULTS: A positive association between healthcare utilisation and increased severity of WMPs was observed. Number of hospitalisations in the past 12 months increased from 0.93 in patients with no WMPs up to 1.11 (mild), 1.17 (moderate) and 1.76 (severe) (PϽ0.0001). Mean annual primary care consultations were 1.7 (no WMPs), 2.0 (mild), 1.9 (moderate) and 2.9 (severe) (PϽ0.0001). Similar patterns of health resource utilisation were observed in time spent with urologists -0.1 (no WMPs), 0.2 (mild), 0.3 (moderate) and 0.6 (severe) (PϽ0.0001), and time spent with physiotherapists (2.0, 4.7, 6.9 and 9.9 respectively, PϽ0.0001). Similar trends were observed with use of wheelchair, walking frame, walking stick and ambulatory support from family and friends. CONCLUSIONS: Increased WMPs are associated with increased use of healthcare resources among MS patients. These results suggest that functional impairment due to mobility problems, including walking, may exert additional economic burden. Therapies that specifically improve patients' walking and mobility could have a positive socio-economic impact.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.